InViragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
12/7/2011 7:14:20 AM
FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. presented results of the Phase 1 clinical trial of DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting today. In this randomized, placebo-controlled study of 96 healthy adults, DENVax was safe and well tolerated and induced significant neutralizing antibody responses to all four dengue virus subtypes. The most frequent adverse events reported were transient local injection site reactions.